Cyclerion Therapeutics Inc (CYCN)
2.98
-0.07
(-2.30%)
USD |
NASDAQ |
Apr 24, 16:00
2.98
0.00 (0.00%)
After-Hours: 20:00
Cyclerion Therapeutics Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2021 | 30.78M |
| September 30, 2021 | 30.86M |
| June 30, 2021 | 55.08M |
| March 31, 2021 | 28.12M |
| December 31, 2020 | 28.09M |
| September 30, 2020 | 28.08M |
| June 30, 2020 | 4.174M |
| Date | Value |
|---|---|
| March 31, 2020 | 175.49M |
| December 31, 2019 | 211.57M |
| September 30, 2019 | 236.39M |
| June 30, 2019 | 262.49M |
| March 31, 2019 | 110.44M |
| December 31, 2018 | 100.94M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.174M
Minimum
Jun 2020
262.49M
Maximum
Jun 2019
99.19M
Average
30.86M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
| Eli Lilly and Co | 3.496B |
| iBio Inc | 10.68M |
| AbbVie Inc | -17.22B |
| Agile Therapeutics Inc | 6.888M |
| NovaBay Pharmaceuticals Inc | 1.91M |